Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by Bortezomib (Velcade)

被引：0
|
作者：
Nemec, P.
Greslikova, H.
Zaoralova, R.
Filkova, H.
Kuglik, P.
Oltova, A.
Pour, L.
Adam, Z.
Krivanova, A.
Krejci, M.
Hajek, R.
机构：
[1] Masaryk Univ, Monoclonal Gammopathy & Multiple Myeloma B, Brno, Czech Republic
[2] Masaryk Univ, Fac Sci, Dept Genet & Mol Biol, Brno, Czech Republic
[3] Masaryk Univ, Univ Hosp Brno, Fac Med, Dept Internal Med Hematooncol & Clin Hematol, Brno, Czech Republic
[4] Univ Hosp Brno, Dept Med Genet, Brno, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [1] Prevalence and Prognostic Impact of Cytogenetic Abnormalities in 220 Patients With Multiple Myeloma
    Abe, Yoshiaki
    Fujisawa, Manabu
    Usui, Yoshiaki
    Narita, Kentaro
    Takeuchi, Masami
    Matsue, Kosei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E29 - E29
  • [2] Bortezomib (Velcade) for multiple myeloma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1161): : 57 - 58
  • [3] Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
    Jian, Yuan
    Chen, Xiaolei
    Zhou, Huixing
    Zhu, Wanqiu
    Liu, Nian
    Geng, Chuanying
    Chen, Wenming
    MEDICINE, 2016, 95 (19)
  • [4] Bortezomib (Velcade®) in multiple myeloma:: Older patients can also benefit
    Konig, Yasmin
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2006, 33 (05) : 466 - 466
  • [5] Bortezomib (Velcade®) in multiple myeloma:: Older patients can also benefit
    Konig, Yasmin
    ONKOLOGIE, 2006, 29 (10): : 486 - 486
  • [6] Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
    Smetana, Jan
    Berankova, Kristina
    Zaoralova, Romana
    Nemec, Pavel
    Greslikova, Henrieta
    Kupska, Renata
    Mikulasova, Aneta
    Frohlich, Jan
    Sevcikova, Sabina
    Zahradova, Lucie
    Krejci, Marta
    Sandecka, Viera
    Almasi, Martina
    Kaisarova, Petra
    Melicharova, Ham
    Adam, Zdenek
    Penka, Miroslav
    Jarkovsky, Jiri
    Jurczyszyn, Arthur
    Hajek, Roman
    Kuglik, Petr
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (02): : 123 - 130
  • [7] The prognostic impact of dynamic changing of cytogenetic abnormalities under the treatment options in multiple myeloma
    Fan Huishou
    Liu Jiahui
    Mao Xuehan
    Zengjun, Lizengjun
    Sui Weiwei
    Du Chenxing
    Deng, Shuhui
    Wang, Tingyu
    Yan, Yuting
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E221 - E222
  • [8] Cytogenetic abnormalities in 13 patients with multiple myeloma
    Sole, F
    Woessner, S
    Acin, P
    PerezLosada, A
    Florensa, L
    Besses, C
    SansSabrafen, J
    CANCER GENETICS AND CYTOGENETICS, 1996, 86 (02) : 162 - 164
  • [9] Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
    Chang, Hong
    Trieu, Young
    Qi, Xiaoying
    Xu, Wei
    Stewart, Keith A.
    Reece, Donna
    LEUKEMIA RESEARCH, 2007, 31 (06) : 779 - 782
  • [10] Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Gkotzamanidou, Maria
    Iakovaki, Marina
    Roussou, Maria
    Efstathiou, Eleni
    Terpos, Evangelos
    BLOOD, 2009, 114 (22) : 395 - 396
12345